Public Policy Resources

The Landscape of Biomarker Testing Coverage in the U.S.

February 28, 2022

Biomarker testing is becoming increasingly important for cancer care because it connects the right patient, to the right treatment, at the right time, however insurance coverage of testing varies widely. This study, that examines administrative claims data to understand the premium impact of expanding biomarker testing coverage in four markets: commercial self-insured large group, small group, individual, and Medicaid, found a small potential impact on insurance premiums as a result of higher utilization of biomarker testing.

PDF icon Download Landscape of Biomarker Testing Coverage in the U.S.

Related Resources

Health Equity in Biomarker Testing and Targeted Therapy

December 19, 2022

Cancer biomarker testing can lead to targeted therapy which can improve survival and quality of life by connecting patients to the most beneficial treatment for their disease.

Read more

Pharmacogenomic (PGx) Testing: Tests Guide Appropriate Drug Selection and Dosing

August 2, 2022

Pharmacogenomic (PGx) testing is a component of precision medicine that involves examining a patient’s inherited genes to detect variations that may impact the way a drug is broken down, absorbed and used within the body. 

Read more